Category: Local News

Categories
Culture Local News Politics

County Clerk to offer free photo ID cards for veterans during Fourth of July holiday

TRENTON, N.J. — As the Fourth of July approaches, Mercer County Clerk Paula Sollami Covello reminds Mercer County residents that for Fourth of July Veteran ID cards will be free on the following days:

 

July 5 to July 15, and (the County Clerk’s Office is closed Monday, July 4)

 

ID cards that indicate a Veteran’s status have become very useful as many stores and home improvement retailers now offer discounts to veterans. Veterans can receive their photo ID cards by visiting the Mercer County Clerk’s Office located on the 2nd Floor of the Old Courthouse at 209 South Broad Street in Trenton.

The Clerk’s I.D. department is open Monday to Friday from 8:30 a.m. to 4:30 p.m. Normally, veterans pay a special reduced fee of $10.00, half the normal price of a general ID card.

 

The requirements for a Mercer County ID card are:

  • Must be a Mercer County resident for at least 6 months.
  • Must produce the following:
    • A valid birth certificate with a raised seal or a naturalization certificate.
    • A valid NJ Motor Vehicle License or voter registration card or, lease agreement.
    • Voting Profile
  • To have their US military veteran status designated on the ID card, veterans must also produce or register their DD-214 honorable discharge papers with the County Clerk’s Office.   

 

RECORDING OF DD-214 

A Certificate of Release – Discharge from Active Duty, or DD-214 Form for short, is generally issued when a service member is honorably discharged from active military duty. The document contains information that is usually needed to verify military service for benefits, retirement, employment, and membership in veterans’ organizations. Additionally, recording a DD-214 Form is free of charge to Mercer County Veterans in the Clerk’s office.

 

“Because military papers can get damaged or lost, veterans should take advantage of the opportunity to file copies of their DD-214 discharge papers with the Clerk’s Office,” said Sollami Covello, whose office maintains and preserves official documents and records for Mercer County.

“If a copy of discharge papers are needed in the future, a veteran, an immediate family member, or a legally recognized representative of their estate may obtain one with proper identification,” noted Sollami Covello.

For further information on how to obtain a Mercer County photo identification card, please call the Clerk’s office at 609-278-7108

Categories
Culture Local News

Juneteenth event at Capital City Farm to highlight African Americans’ impact on agriculture

TRENTON, N.J. — The Mercer County Park Commission is celebrating Juneteenth by highlighting the contributions of African Americans, past and present, in agriculture and food advocacy at Capital City Farm on Saturday.

 

 

The family-friendly event at this urban farm in the City of Trenton, will take place from 10 a.m. to 3 p.m., June 18.

There will be activities engaging youngsters and supporting the Trenton Literacy Movement by distributing free children’s books to a Literacy Corner where children can sit on hay bales and read with their parents and local volunteers. There will also be a scavenger hunt during which participants will find answers all around the farm to the clues in their “passports.” The first 50 hunters who complete their passports will receive $10 bookstore gift cards.

Hands-on activities including corn milling, lettuce seedling planting, and bee abode building will keep the young people busy as they listen to live music and taste African-inspired recipes. Fresh produce grown on the farm will also be available, free of charge, while supplies last.

 

 

Farm visitors will be invited to take a tour of the farm, which is deceptively larger than it looks. Crops include all sorts of vegetables, such as carrots, kale and collards, flowers and fruits. While touring, guests will also learn a little about Booker T. Whatley, Tuskegee University agricultural professor; Dr. James Still, New Jersey’s “Black Doctor of the Pines” and self-taught botanist; Meredith Taylor, a Rutgers University professor whose research focuses on urban agriculture; and many other familiar and unfamiliar people and organizations.

 

Community partners who have contributed to this event include the New Jersey Conservation Foundation, the Garden State Agrihood Project, the Conservatory of Music and Performing Arts Society, and the Conservatory Mansion. The Center for Child and Family Achievement, The Watershed Institute, and the African American Cultural Collaborative contributed the children’s books.

Capital City Farm is located at 301 North Clinton Ave. in Trenton. For more information about the farm, visit the Mercer County Park Commission website.

Categories
Culture Local News

Juneteenth program at Howell Farm to feature tours of historical farmhouse

HOPEWELL TOWNSHIP, N.J. — Visitors to Howell Living History Farm can join historical interpreters on a free wagon ride and tour of the circa-1790 farmhouse, where Revolutionary War-era New Jerseyans lived and farmed the land that now makes up Mercer County’s Pleasant Valley National Rural Historic District, Saturday, June 18.

 

Photos: The Captain Henry Phillips House and historical interpreter Ivey Avery.

 

Saturday’s program is being held in observance of Juneteenth, which commemorates the emancipation of enslaved African-Americans.

Tours begin at 10:30 a.m. in the barnyard, where visitors will board a wagon to travel down the driveway, across Moore’s Creek and through the woods before disembarking at the Captain Henry Phillips House. There they’ll meet historical interpreters Ivey Avery of Trenton and Pete Curtis of George Washington’s Mount Vernon, who will be wearing period attire for a unique discussion of the history of the house and the people who lived in it before and after the 1804 passage of New Jersey’s Act for the Gradual Abolition of Slavery.

Avery and Curtis are experienced historical interpreters who have presented the lives of Black Americans throughout our history, in both first- and third-person styles. With additional support from Howell Farm historian Larry Kidder, they will guide visitors through the house and tell the story of Nance, an enslaved woman who lived there with her children, while also discussing the ways that other Black residents of Pleasant Valley lived before, during and after the abolition of slavery in New Jersey. Following the tour, light refreshments will be served outside.

 

 

Wagon tours depart from the barnyard at 10:30 and 11:30 a.m., and 12:30, 1:30 and 2:30 p.m., and are limited to 20 participants per session. Up to 10 spaces per tour may be reserved online via the Mercer County Park Commission CommunityPassportal, and the remaining 10 will be kept available for walk-ins on a first-come, first-served basis.

Guided tours of the circa-1900 “Howell Farm farmhouse” will also be offered throughout the day, beginning at 11 a.m., 12 noon, and 1, 2 and 3 p.m. The farm will be open from 10 a.m. to 4 p.m. Tours of both farmhouses, as well as admission to the farm, are free.

Howell Farm is owned by the County of Mercer and operated by the Mercer County Park Commission. It is located at 70 Woodens Lane, Hopewell Township, NJ 08530. For more information, please visit www.howellfarm.org or call the farm office at 609-737-3299.

Categories
Local News Travel & Leisure

Trenton-Mercer Airport manager receives leadership award from aviation professionals’ organization

EWING, N.J. — Trenton-Mercer Airport, Manager Melinda Montgomery, A.A.E, received the Leadership Award for her “outstanding” work as Committee Advisor to the American Association of Airport Executives (AAAE) Young Professionals Committee, and for her “dedication and commitment to the aviation industry.”

 

Photo: Melinda Montgomery, Trenton-Mercer Airport manager, accepts the American Association of Airport Executives Leadership Award from AAAE Chairman Laurence J. Krauter, AAE, AICP, at the 94th Annual Conference and Exposition in Seattle June 6-8, 2022.

 

The award was presented to Ms. Montgomery by AAAE Chairman Laurence J. Krauter, AAE, AICP, at the 94th Annual Conference and Exposition, held this year June 6-8 in Seattle.

 

“Melinda Montgomery’s work at Trenton-Mercer Airport has never been contained by a perimeter fence,” said Mercer County Executive Brian M. Hughes. “She eagerly shares her enthusiasm about our airport and the industry in general, and I heartily congratulate her on being recognized by her peers for her leadership with young professionals in the field of airport management.”

 

At the conference, Ms. Montgomery, of Hamilton Township, passed the gavel after completing her term as president of the Northeast Chapter of AAAE, and was named to the organization’s Board of Directors. Additionally, she sits on the AAAE Policy Review Council.

 

Photo: Melinda Montgomery, seventh from left, with members of the AAAE Young Professionals Committee at the 94th Annual Conference.

 

Founded in 1928, AAAE is the world’s largest airport professional organization representing individuals who work at public-use commercial and general aviation airports.

 

Trenton-Mercer Airport, which celebrated its 90th anniversary in 2019, serves as a valuable transportation hub and economic engine for the entire region. As airport manager, Ms. Montgomery directs, plans, manages and organizes the daily operations of the airside, landside and terminal operations of the county-owned facility, one of three commercial airports in New Jersey.

 

Located in Ewing Township, the airport is home to commercial air carrier service connecting nearly 1 million customers each year to an array of destinations. More than 20 aviation tenants including the aviation units of a number of Fortune 500 companies, the New Jersey State Police and the New Jersey National Guard, and two general aviation service facilities also are located at Trenton-Mercer.

Categories
Business Local News

Bristol Myers Squibb withdraws supplemental biologics license application (sBLA) for Reblozyl® (luspatercept-aamt) for non-transfusion dependent (NTD) Beta Thalassemia

PRINCETON, N.J. — (BUSINESS WIRE) — Bristol Myers Squibb (NYSE: BMY) today announced that the company has withdrawn a supplemental biologics license application (sBLA) for Reblozyl® (luspatercept-aamt) for the treatment of anemia in adults with non-transfusion dependent (NTD) beta thalassemia. The Company could not appropriately address the U.S. Food and Drug Administration’s questions about the benefit-risk profile of Reblozyl in this patient population based on the current dataset from the Phase 2 BEYOND trial.

“While we will not pursue this indication in the U.S., we’re continuing to evaluate Reblozyl in a broad clinical development program to bring this important therapeutic option to more patients living with the burden of anemia,” said Noah Berkowitz, M.D., Ph.D., senior vice president, Hematology Development, Bristol Myers Squibb.

 

Reblozyl, a first-in-class therapeutic option, is currently approved in the United States, European Union and Canada to address transfusion-dependent anemia-associated beta thalassemia and lower-risk myelodysplastic syndromes.

 

About BEYOND

BEYOND (NCT03342404) is a Phase 2, double-blind, randomized, placebo-controlled, multicenter study to determine the efficacy and safety of luspatercept-aamt (ACE-536) versus placebo in adults with non-transfusion dependent beta thalassemia. The study is divided into the screening period, double-blind treatment period (DBTP) and post-treatment follow-up period (PTFP) and randomized 145 subjects at a 2:1 ratio of Reblozyl versus placebo. All patients were eligible to receive best supportive care, which included red blood cell transfusions; iron-chelating agents; use of antibiotic, antiviral, and antifungal therapy; and/or nutritional support, as needed. The primary endpoint of the study is the proportion of subjects who have an increase from baseline ≥1.0 g/dL in mean of hemoglobin values over a continuous 12-week interval from Week 13 to Week 24 of treatment in the absence of transfusions. Key secondary endpoints include mean change in non-transfusion dependent beta thalassemia-patient reported outcome (NTDT-PRO) Tiredness and Weakness (TW) domain score and baseline hemoglobin (Hb).

 

About Beta Thalassemia

Beta thalassemia is an inherited blood disorder caused by a genetic defect in hemoglobin. It is one of the most common autosomal recessive disorders, and the total annual incidence of symptomatic individuals is estimated at 1 in 100,000 people globally.1 While beta thalassemia remains a rare disease, its prevalence has increased in the United States by approximately 7.5% over the last 50 years.2 The disease is associated with ineffective erythropoiesis, which results in the production of fewer and less healthy red blood cells (RBCs), often leading to severe anemia—a condition that can be debilitating and can lead to other complications for patients—as well as other serious health issues.3 Treatment options for anemia associated with beta thalassemia are limited, consisting mainly of frequent RBC transfusions that have the potential to contribute to iron overload, which can cause serious complications such as organ damage.1 Non-transfusion dependent beta thalassemia is a term used to describe patients who do not require lifelong regular transfusions for survival, although they may experience a range of clinical complications and require occasional or even frequent transfusions, usually for defined periods of time.4

 

About Reblozyl®

Reblozyl, a first-in-class therapeutic option, promotes late-stage red blood cell maturation in animal models.1 Reblozyl is being developed and commercialized through a global collaboration with Merck following Merck’s acquisition of Acceleron Pharma, Inc. in November 2021. Reblozyl is currently approved in the U.S. for the treatment of:

 

  • anemia in adult patients with beta thalassemia who require regular red blood cell transfusions, and
  • anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T).

 

Reblozyl is not indicated for use as a substitute for red blood cell transfusions in patients who require immediate correction of anemia.

 

Important Safety Information

WARNINGS AND PRECAUTIONS

Thrombosis/Thromboembolism

In adult patients with beta thalassemia, thromboembolic events (TEE) were reported in 8/223 (3.6%) REBLOZYL-treated patients. TEEs included deep vein thrombosis, pulmonary embolus, portal vein thrombosis, and ischemic stroke. Patients with known risk factors for thromboembolism (splenectomy or concomitant use of hormone replacement therapy) may be at further increased risk of thromboembolic conditions. Consider thromboprophylaxis in patients at increased risk of TEE. Monitor patients for signs and symptoms of thromboembolic events and institute treatment promptly.

 

Hypertension

Hypertension was reported in 10.7% (61/571) of REBLOZYL-treated patients. Across clinical studies, the incidence of Grade 3 to 4 hypertension ranged from 1.8% to 8.6%. In patients with beta thalassemia with normal baseline blood pressure, 13 (6.2%) patients developed systolic blood pressure (SBP) ≥130 mm Hg and 33 (16.6%) patients developed diastolic blood pressure (DBP) ≥80 mm Hg. In adult patients with MDS with normal baseline blood pressure, 26 (29.9%) patients developed SBP ≥130 mm Hg and 23 (16.4%) patients developed DBP ≥80 mm Hg. Monitor blood pressure prior to each administration. Manage new or exacerbations of preexisting hypertension using anti-hypertensive agents.

 

Embryo-Fetal Toxicity

REBLOZYL may cause fetal harm when administered to a pregnant woman. REBLOZYL caused increased post-implantation loss, decreased litter size, and an increased incidence of skeletal variations in pregnant rat and rabbit studies. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment and for at least 3 months after the final dose.

 

ADVERSE REACTIONS

Beta Thalassemia

  • Serious adverse reactions occurred in 3.6% of patients on REBLOZYL. Serious adverse reactions occurring in 1% of patients included cerebrovascular accident and deep vein thrombosis. A fatal adverse reaction occurred in 1 patient treated with REBLOZYL who died due to an unconfirmed case of acute myeloid leukemia (AML).
  • Most common adverse reactions (at least 10% for REBLOZYL and 1% more than placebo) were headache (26% vs 24%), bone pain (20% vs 8%), arthralgia (19% vs 12%), fatigue (14% vs 13%), cough (14% vs 11%), abdominal pain (14% vs 12%), diarrhea (12% vs 10%) and dizziness (11% vs 5%).

 

Myelodysplastic Syndromes

  • Grade >3 (≥2%) adverse reactions included fatigue, hypertension, syncope and musculoskeletal pain. A fatal adverse reaction occurred in 5 (2.1%) patients.
  • The most common (≥10%) adverse reactions included fatigue, musculoskeletal pain, dizziness, diarrhea, nausea, hypersensitivity reactions, hypertension, headache, upper respiratory tract infection, bronchitis, and urinary tract infection.

 

LACTATION

It is not known whether REBLOZYL is excreted into human milk or absorbed systemically after ingestion by a nursing infant. REBLOZYL was detected in milk of lactating rats. When a drug is present in animal milk, it is likely that the drug will be present in human milk. Because many drugs are excreted in human milk, and because of the unknown effects of REBLOZYL in infants, a decision should be made whether to discontinue nursing or to discontinue treatment. Because of the potential for serious adverse reactions in the breastfed child, breastfeeding is not recommended during treatment and for 3 months after the last dose.

 

Please see full Prescribing Information for REBLOZYL.

Bristol Myers Squibb: Creating a Better Future for People with Cancer

Bristol Myers Squibb is inspired by a single vision — transforming people’s lives through science. The goal of the company’s cancer research is to deliver medicines that offer each patient a better, healthier life and to make cure a possibility. Building on a legacy across a broad range of cancers that have changed survival expectations for many, Bristol Myers Squibb researchers are exploring new frontiers in personalized medicine, and through innovative digital platforms, are turning data into insights that sharpen their focus. Deep scientific expertise, cutting-edge capabilities and discovery platforms enable the company to look at cancer from every angle. Cancer can have a relentless grasp on many parts of a patient’s life, and Bristol Myers Squibb is committed to taking actions to address all aspects of care, from diagnosis to survivorship. Because as a leader in cancer care, Bristol Myers Squibb is working to empower all people with cancer to have a better future.

 

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook and Instagram.

 

Juno Therapeutics, Inc. is a wholly owned subsidiary of Bristol-Myers Squibb Company. In certain countries outside the U.S., due to local laws, Celgene and Juno Therapeutics are referred to as, Celgene, a Bristol Myers Squibb company and Juno Therapeutics, a Bristol Myers Squibb company.

 

Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the research, development and commercialization of pharmaceutical products. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements are based on current expectations and projections about our future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond our control and could cause our future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. These risks, assumptions, uncertainties and other factors include, among others, the possibility that Reblozyl (luspatercept-aamt) may not receive regulatory approval for the additional indication described in this release in the currently anticipated timeline or at all, that any marketing approvals, if granted, may have significant limitations on their use, and, if approved, whether such product candidate for such additional indication described in this release will be commercially successful. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol Myers Squibb’s business and market, particularly those identified in the cautionary statement and risk factors discussion in Bristol Myers Squibb’s Annual Report on Form 10-K for the year ended December 31, 2021, as updated by our subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, Bristol Myers Squibb undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.

 

corporatefinancial-news

 

References:

  1. Galanello R, Origa R. Beta thalassemia. Orphanet Journal of Rare Diseases. 2010;5(11). Available at: https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-5-11. Accessed February 2022.
  2. Kattamis, A., Forni, G. L., Aydinok, Y., Viprakasit, V. (2020). Changing patterns in the epidemiology of β-thalassemia. Available at: https://onlinelibrary.wiley.com/doi/full/10.1111/ejh.13512. Accessed February 2022.
  3. Rivella, S. (2013). Ineffective erythropoiesis and thalassemias. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3703923/pdf/nihms-490109.pdf. Accessed February 2022.
  4. Musallam, K. M., Rivella, S., Vichinsky, E., & Rachmilewitz, E. A. (2013). Non-transfusion-dependent thalassemias. Haematologica, 98(6), 833–844. https://doi.org/10.3324/haematol.2012.066845. Accessed February 2022.

Contacts

BMS:

Media Inquiries: media@bms.com
Investors: investor.relations@bms.com

Categories
Business Lifestyle Local News

Universal Display Corporation and Adesis, Inc. announce sponsorship and participation in MARM 2022

EWING, N.J. — (BUSINESS WIRE) — $OLED #AdesisInc—Universal Display Corporation (Nasdaq: OLED), enabling energy-efficient displays and lighting with its UniversalPHOLED® technology and materials, and Adesis, Inc., a leading contract research organization and a wholly-owned subsidiary of Universal Display Corporation (UDC), today announced its sponsorship and participation in the 2022 Middle Atlantic Regional Meeting (MARM) of the American Chemical Society (ACS), which will be held June 1-4 at The College of New Jersey. This year’s MARM theme is “Our Chemical Revolution,” and will emphasize diversity, equity, and inclusion, highlight advances in science and recognize the achievements of outstanding chemists.

“With Universal Display and Adesis being leaders in chemistry innovation and commercialization, we are pleased to sponsor and participate in the 50th Middle Atlantic Regional Meeting,” said Steven V. Abramson, President and Chief Executive Officer of Universal Display Corporation. “MARM brings together leading scientists to discuss the latest advances in chemistry, molecular modeling, nanotechnology, polymer science, and related fields. As a pioneering technology innovator, UDC supports an expanding range of educational initiatives designed to inspire and encourage future generations interested in Science, Technology, Engineering and Math (STEM) fields. We are delighted to support regional students with conference scholarships to attend MARM and to sponsor the research poster session.”

 

Universal Display Corporation and Adesis, Inc. are sponsors of MARM 2022. Universal Display is sponsoring conference registration for ten students, which will be distributed equitably by conference organizers. Adesis is a research poster session sponsor. In addition, UDC and Adesis will be on-site for the MARM expo and career fair. Participants for MARM 2022 include:

 

  • Dr. George Fitzgerald, Director of Computational Chemistry of UDC, is MARM 2022’s Division Chair for Industrial and Engineering Chemistry. Dr. Fitzgerald recruited symposia organizers in the areas of Organic Synthesis, Applications of Crystal Engineering, Sustainable Chemistry, Molecular Modeling, and Advances in Battery Technology.
  • Linda MacDonald, Chief Operating Officer of Adesis, will give a presentation on breaking brain barriers to effect successful organizational change titled, “Leading Change.”
  • Dr. Zhenzhen Dong, Associate Director of Chemistry of Adesis, organized a symposium on organic chemistry, “Pairings in Organic Chemistry,” where speakers will present different aspects of current research challenges.
  • Dr. Rasha Hamze, Senior Research Scientist of UDC, will give a presentation on her research into luminescent materials titled, “Luminescence of Heavy and Light Metals.”
  • Dr. Elena Sheina, Senior Research Scientist of UDC, organized a symposium on “Advances in Battery Technology for the 21st Century,” featuring the latest work from both academic and commercial research scientists.
  • Dr. Joseph Macor, Senior Research Scientist of UDC, as general MARM volunteer in his role as Board Member of the Trenton Local Section of ACS.

 

About Universal Display Corporation

Universal Display Corporation (Nasdaq: OLED) is a leader in the research, development and commercialization of organic light emitting diode (OLED) technologies and materials for use in display and solid-state lighting applications. Founded in 1994 and with subsidiaries and offices around the world, the Company currently owns, exclusively licenses or has the sole right to sublicense more than 5,500 patents issued and pending worldwide. Universal Display licenses its proprietary technologies, including its breakthrough high-efficiency UniversalPHOLED® phosphorescent OLED technology that can enable the development of energy-efficient and eco-friendly displays and solid-state lighting. The Company also develops and offers high-quality, state-of-the-art UniversalPHOLED materials that are recognized as key ingredients in the fabrication of OLEDs with peak performance. In addition, Universal Display delivers innovative and customized solutions to its clients and partners through technology transfer, collaborative technology development and on-site training. To learn more about Universal Display Corporation, please visit https://oled.com/.

 

About Adesis, Inc.

As a wholly-owned subsidiary of Universal Display Corporation, Adesis is a contract research organization (CRO) supporting the pharma, biotech, catalysis and a number of other industries. The CRO specializes in organic and organometallic synthesis, in milligrams to multi-kilogram quantities. Adesis has a business model of providing clients with organic chemistry services in three areas: early stage research, scale up and development, and specialty manufacturing. With over 20 years of success and approximately 100 chemists with extensive industry and professional experience, Adesis supports companies in various industries with small molecule organic chemistry expertise. Adesis provides a range of services that can supplement research and development efforts. It can also act as a specialty manufacturer to reinforce supply chains and protect sensitive intellectual property. To learn more about Adesis, please visit http://adesisinc.com/.

 

Universal Display Corporation and the Universal Display Corporation logo are trademarks or registered trademarks of Universal Display Corporation. All other company, brand or product names may be trademarks or registered trademarks.

 

All statements in this document that are not historical, such as those relating to the projected adoption, development and advancement of the Company’s technologies, and the Company’s expected results and future declaration of dividends, as well as the growth of the OLED market and the Company’s opportunities in that market, are forward-looking financial statements within the meaning of the Private Securities Litigation Reform Act of 1995. You are cautioned not to place undue reliance on any forward-looking statements in this document, as they reflect Universal Display Corporation’s current views with respect to future events and are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated. These risks and uncertainties are discussed in greater detail in Universal Display Corporation’s periodic reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission, including, in particular, the section entitled “Risk Factors” in Universal Display Corporation’s Annual Report on Form 10-K for the year ended December 31, 2021. Universal Display Corporation disclaims any obligation to update any forward-looking statement contained in this document.

 

Follow Universal Display Corporation

Twitter
Facebook
YouTube

(OLED-C)

Contacts

Universal Display Contact:
Darice Liu

investor@oled.com
media@oled.com
+1 609-964-5123

Categories
Environment Lifestyle Local News Sports & Gaming

Park Commission opens Hopewell Valley Golf Course

The Mercer County Park Commission and the County of Mercer held a ribbon-cutting ceremony to celebrate the grand opening of the Hopewell Valley Golf Course, a newly acquired property of the Park Commission.

 

Photo: Ribbon-cutting with Park Commission Executive Director Aaron T. Watson and dignitaries.

 

This 186-acre, 18-hole course includes a clubhouse, ballroom, three Har-Tru tennis courts, three platform tennis courts and a pool. The facility is now fully operational and open to the public and provides new amenities for residents of the County and beyond.

 

“Most of our active recreational facilities are located in our main park in West Windsor, and I am pleased that residents in this part of our beautiful County now have a top-notch park where they can swim, play golf and tennis, and dine, all while taking in spectacular views,’’ said Mercer County Executive Brian M. Hughes.

 

Photo: A view of the golf course from the clubhouse.

 

At the ribbon-cutting celebration, Park Commission Executive Director Aaron T. Watson was joined by Chief of Staff Kelvin S. Ganges, County Administrato, Lillian L. Nazzaro, Planning Director Leslie Floyd, County Commissioners Nina Melker, Lucylle Walter and Andrew Koontz, and members of the Park Commission. Signing of the first tee flag and ceremonial first tee shot, taken by Park Commission President James Schulz, were honored in celebration of the full opening of the course.

 

“This facility opens so much potential for the Park Commission and we are thrilled to finally be able to welcome the public to this incredible new asset,” Mr. Watson said. “This acquisition expands our golf and tennis offerings, and the addition of a pool gives us the opportunity to provide something new and exciting in the County and opens the door to new programs and events at this location.”

 

Photo: From left, Park Commission Deputy Director Joe Pizza; Bert Sanford, a Hopewell Valley Golf Club member for more than 55 years who boasts two career holes-in-one; and Park Commission Executive Director Aaron T. Watson.

 

Mercer County’s award-winning Tennis Center is located in Mercer County Park, and the county operates four additional golf courses.

 

Hopewell Valley Golf Club is located on Pennington-Hopewell Road in Hopewell Township. The tennis courts and pool are open from Memorial Day to Labor Day and the golf course and club house are open year-round, course conditions weather permitting.

 

To book a tee time for Hopewell Valley Golf Course, visitwww.golfmercercounty.com. For tennis reservations, call (609) 448-8007. Mercer County Tennis ID holders can book a court usingwww.courtreserve.com. Pool sessions must be booked online through Community Pass. Users can create an account and register for an early or afternoon session byclicking here.

Categories
Culture Local News

Trenton-Mercer Airport conducts required-FAA exercise

 TRENTON, N.J. — Front-line responders from more than a dozen Mercer County, State, and municipal agencies, as well as other emergency stakeholders, took part in a federally required Airport Emergency Plan (AEP) Review conducted by Trenton-Mercer Airport last Wednesday.

 

Under FAA regulations, Trenton-Mercer Airport must complete an AEP review annually. In 2023, the airport will conduct a full-scale emergency drill, which it does every three years as mandated by the FAA. Photo: Trenton-Mercer Airport Manager Melinda Montgomery leads a review of the Airport Emergency Plan on May 25, 2022.

 

The purpose of the event held May 25 at the Township of Ewing’s conference center, was to fully review and discuss the AEP to ensure that the document continues to be maintained in a manner consistent with the National Incident Management System/Incident Command System. A “Table-top” review also was performed, where participants discussed a fictional emergency scenario and their agencies proposed responses to it.

 

“Should a major incident occur at Trenton-Mercer Airport, agencies at the local, state and federal levels must be able to provide a seamlessly coordinated response,” said Mercer County Executive Brian M. Hughes. “This review allows emergency stakeholders to familiarize themselves with the plan and each other, thereby increasing the effectiveness of our response in the event of an actual airport emergency.”

 

In addition to Trenton-Mercer Airport staff, TTN Aircraft Rescue and Firefighting (ARFF)-Station 34, and Mercer County Sheriff’s Office, Airport Division, a number of other County agencies were represented, including the County Executive’s Office, Office of Emergency Management (OEM), Emergency Services Communications Center, County coordinators for EMS and Fire, and the Prosecutor’s Office. Representatives from the Federal Aviation Administration (FAA), Transportation Security Administration, FBI, New Jersey State Police Aviation Unit, New Jersey Office of Homeland Security, New Jersey Office of Emergency Management, Midwest Air Traffic Control Services, New Jersey Division of Aeronautics, Ewing Township Police Department, Ewing Emergency Medical Services (EMS), Ewing OEM, West Trenton Fire Company-Station 33, Prospect Heights Volunteer Fire Co., Ewing Township Fire Co., Capital Health, Frontier Airlines, Philadelphia International Airport, and Worldwide Flight Services also participated.

 

Under FAA regulations, Trenton-Mercer Airport must complete an AEP review annually. In 2023, the airport will conduct a full-scale emergency drill, which it does every three years as mandated by the FAA.

Categories
Business Healthcare Local News Science

U.S. Food and Drug Administration approves two Opdivo® (nivolumab)-based regimens as first-line treatments for unresectable advanced or metastatic esophageal squamous cell carcinoma

Opdivo in combination with chemotherapy and Opdivo plus Yervoy® (ipilimumab) approved based on a Phase 3 trial showing improved overall survival versus chemotherapy alone1,2

Opdivo-based treatments are now approved for five indications in upper gastroesophageal cancers1

 

PRINCETON, N.J. — (BUSINESS WIRE) — $BMY #CheckMate—Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved both Opdivo® (nivolumab) (injection for intravenous use) in combination with fluoropyrimidine- and platinum-containing chemotherapy and Opdivo® plus Yervoy® (ipilimumab) as a first-line treatment for adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) regardless of PD-L1 status. The approvals are based on the Phase 3 CheckMate -648 trial, which evaluated Opdivo in combination with chemotherapy (n=321) and Opdivo plus Yervoy (n=325) each compared to chemotherapy alone (n=324), and was the largest Phase 3 trial of an immunotherapy in first-line ESCC.1

In the trial, Opdivo in combination with chemotherapy demonstrated superior overall survival (OS) compared to chemotherapy alone, both in all randomized patients, a secondary endpoint, which was hierarchically tested (Hazard Ratio [HR] 0.74, 95% Confidence Interval [CI]: 0.61 to 0.90, P=0.0021) and in patients whose tumors express PD-L1 (≥1%), a primary endpoint (HR 0.54, 95% CI: 0.41 to 0.71, P<0.0001).1,2 In all randomized patients the median OS (mOS) was 13.2 months (95% CI: 11.1 to 15.7) with Opdivo in combination with chemotherapy versus 10.7 months (95% CI: 9.4 to 11.9) with chemotherapy alone.1 In patients whose tumors express PD-L1 (≥1%) the mOS was 15.4 months (95% CI: 11.9 to 19.5) for Opdivo in combination with chemotherapy versus 9.1 months (95% CI: 7.7 to 10) with chemotherapy alone.1 The median progression-free survival (PFS) in all randomized patients, which was a hierarchically tested secondary endpoint, was 5.8 months (95% CI: 5.6 to 7.0) for Opdivo in combination with chemotherapy and 5.6 months (95% CI: 4.3 to 5.9) for chemotherapy alone (HR= 0.81; 95% CI: 0.67 to 0.99, P=not significant). Per pre-specified analysis, PFS did not meet statistical significance.1 The median PFS in patients whose tumors express PD-L1 (≥1%), which was a co-primary endpoint, was 6.9 months (95% CI: 5.7 to 8.3) for Opdivo in combination with chemotherapy and 4.4 months (95% CI: 2.9 to 5.8) for chemotherapy alone (HR 0.65; 95% CI: 0.49 to 0.86, P=0.0023).1

 

Opdivo plus Yervoy also improved OS compared to chemotherapy in all-randomized patients, a secondary endpoint, which was hierarchically tested (HR 0.78, 95% CI: 0.65 to 0.95, P=0.0110) and patients whose tumors express PD-L1 (≥1%), a primary endpoint (HR 0.64, 95% CI: 0.49 to 0.84, P=0.0010).1,2 The mOS was 12.8 months (95% CI: 11.3 to 15.5) with Opdivo plus Yervoy versus 10.7 months (95% CI: 9.4 to 11.9) with chemotherapy alone in all randomized patients and 13.7 months (95% CI: 11.2 to 17.0) with Opdivo plus Yervoy versus 9.1 months (95% CI: 7.7 to 10) with chemotherapy alone in patients whose tumors express PD-L1 (≥1%).1 The median PFS in patients whose tumors express PD-L1 (≥1%), which was a co-primary endpoint, was 4.0 months (95% CI: 2.4 to 4.9) for Opdivo plus Yervoy and 4.4 months (95% CI: 2.9 to 5.8) for chemotherapy alone (HR 1.02; 95% CI: 0.78 to 1.34, P=not significant). Per pre-specified analysis, PFS did not meet statistical significance.1,2 Median PFS in the PD-L1 (≥1%) population was not statistically significant and therefore it was not hierarchically tested in the all comers population.

 

Opdivo alone and Opdivo plus Yervoy are associated with the following Warnings and Precautions: severe and fatal immune-mediated adverse reactions including pneumonitis, colitis, hepatitis and hepatotoxicity, endocrinopathies, nephritis and renal dysfunction, dermatologic adverse reactions, other immune-mediated adverse reactions; infusion-related reactions; complications of allogeneic hematopoietic stem cell transplantation (HSCT); embryo-fetal toxicity; and increased mortality in patients with multiple myeloma when Opdivo is added to a thalidomide analogue and dexamethasone, which is not recommended outside of controlled clinical trials.1 Please see the Important Safety Information section below.

 

“Today brings welcome news for many advanced or metastatic esophageal squamous cell carcinoma patients and oncologists,” said Jaffer A. Ajani, M.D., CheckMate -648 co-first author and lead U.S. investigator, and professor of Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center. “Unresectable advanced or metastatic esophageal squamous cell carcinoma is a challenging disease, and there’s a need for additional treatment options that may extend survival in the first-line setting.3,4 In the CheckMate -648 trial, two nivolumab-based combinations showed a survival benefit compared to chemotherapy alone, offering new treatment options regardless of PD-L1 status.”1

 

This application was reviewed under the FDA’s Real-Time Oncology Review (RTOR) pilot program, which aims to ensure that safe and effective treatments are available to patients as early as possible.5

 

“At Bristol Myers Squibb, we recognize the need that exists for many patients facing upper gastroesophageal cancers, including advanced or metastatic esophageal squamous cell carcinoma, and we are focused on our goal to bring forward new treatment options with proven survival benefits regardless of PD-L1 status and histology,” said Adam Lenkowsky, senior vice president and general manager, U.S., Cardiovascular, Immunology, Oncology, Bristol Myers Squibb.6 “Today’s approvals bring two first-line immunotherapy-based treatment options at once, Opdivo in combination with chemotherapy and Opdivo plus Yervoy as the first dual immunotherapy option, to newly diagnosed patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, further building on the role of Opdivo-based regimens in upper gastroesophageal cancers.”1

 

About CheckMate -648

CheckMate -648 is a randomized Phase 3 study evaluating Opdivo plus Yervoy or Opdivo in combination with chemotherapy (fluorouracil and cisplatin) against chemotherapy (fluorouracil plus cisplatin) alone in adult patients with previously untreated unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma.1,2 The primary endpoints of the trial are overall survival (OS) and progression-free survival (PFS) determined by blinded independent central review (BICR) in patients whose tumors express PD-L1 (≥1%) for both Opdivo-based combinations versus chemotherapy.2 Secondary endpoints of the trial, including OS and PFS as determined by BICR in the all randomized population, were tested hierarchically only if corresponding primary endpoints were significant.1,2

 

In the Opdivo plus Yervoy arm, patients received treatment with Opdivo 3 mg/kg every 2 weeks and Yervoy 1 mg/kg every 6 weeks up to 2 years or until disease progression or unacceptable toxicity.1,2 In the Opdivo in combination with chemotherapy arm, patients received treatment with Opdivo 240 mg on Day 1 and Day 15, fluorouracil 800 mg/m²/day on Day 1 through Day 5 for five days, and cisplatin 80 mg/m² on Day 1 of a four-week cycle.1,2 Patients were treated with Opdivo until disease progression, unacceptable toxicity, or up to 2 years.1,2 In patients who received Opdivo in combination with chemotherapy and in whom either fluorouracil and/or cisplatin were discontinued, other components of the treatment regimen were allowed to be continued. 2 Patients who discontinued combination therapy because of an adverse reaction attributed to ipilimumab were permitted to continue Opdivo as a single agent.2

 

Select Safety Profile from CheckMate -648 Study

Opdivo and/or chemotherapy were discontinued in 39% of patients and were delayed in 71% of patients for an adverse reaction.1 Serious adverse reactions occurred in 62% of patients receiving Opdivo in combination with chemotherapy.1 The most frequent (≥2%) serious adverse reactions in patients receiving Opdivo in combination with chemotherapy were pneumonia (11%), dysphagia (7%), esophageal stenosis (2.9%), acute kidney injury (2.9%), and pyrexia (2.3%).1 Fatal adverse reactions occurred in 5 (1.6%) patients treated with Opdivo in combination with chemotherapy; these included pneumonitis, pneumatosis intestinalis, pneumonia, and acute kidney injury.1 The most common (≥20%) adverse reactions in patients treated with Opdivo in combination with chemotherapy were nausea (65%), decreased appetite (51%), fatigue (47%), constipation (44%), stomatitis (44%), diarrhea (29%), and vomiting (23%).1

 

Opdivo and/or Yervoy were discontinued in 23% of patients and were delayed in 46% of patients for an adverse reaction.1 Serious adverse reactions occurred in 69% of patients receiving Opdivo plus Yervoy.1 The most frequent (≥2%) serious adverse reactions in patients receiving Opdivo plus Yervoy were pneumonia (10%), pyrexia (4.3%), pneumonitis (4%), aspiration pneumonia (3.7%), dysphagia (3.7%), hepatic function abnormal (2.8%), decreased appetite (2.8%), adrenal insufficiency (2.5%), and dehydration (2.5%).1 Fatal adverse reactions occurred in 5 (1.6%) patients treated with Opdivo plus Yervoy; these included pneumonitis, interstitial lung disease, pulmonary embolism, and acute respiratory distress syndrome.1 The most common (≥20%) adverse reactions in patients treated with Opdivo plus Yervoy were rash (31%), fatigue (28%), pyrexia (23%), nausea (22%), diarrhea (22%), and constipation (20%).1

 

About Esophageal Cancer

In the United States, it is estimated that approximately 20,640 new cases of esophageal cancer will be diagnosed and approximately 16,410 deaths will result from the disease in 2022 alone.7 Esophageal cancer, which can impact the patient’s ability to swallow and eat, is a type of gastroesophageal cancer that starts in the inner layer of the esophagus (the mucosa) and grows.8,9 The mucosa is normally lined with squamous cells.9 Cancer starting in these cells is called squamous cell carcinoma, which is most often found in the upper and middle part of the esophagus, and accounts for less than 30% of esophageal cancers in the United States.9 For about 39% of patients, esophageal cancer is diagnosed in the advanced stage, which is typically harder to treat.10

 

INDICATIONS

OPDIVO® (nivolumab) is indicated for the treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.

 

OPDIVO® (nivolumab) is indicated for the adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in adult patients who have received neoadjuvant chemoradiotherapy (CRT).

 

OPDIVO® (nivolumab), in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC).

 

OPDIVO® (nivolumab), in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC).

 

OPDIVO® (nivolumab), in combination with fluoropyrimidine- and platinum- containing chemotherapy, is indicated for the treatment of adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.

 

IMPORTANT SAFETY INFORMATION

Severe and Fatal Immune-Mediated Adverse Reactions

Immune-mediated adverse reactions listed herein may not include all possible severe and fatal immune-mediated adverse reactions.

 

Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue. While immune-mediated adverse reactions usually manifest during treatment, they can also occur after discontinuation of OPDIVO or YERVOY. Early identification and management are essential to ensure safe use of OPDIVO and YERVOY. Monitor for signs and symptoms that may be clinical manifestations of underlying immune-mediated adverse reactions. Evaluate clinical chemistries including liver enzymes, creatinine, adrenocorticotropic hormone (ACTH) level, and thyroid function at baseline and periodically during treatment with OPDIVO and before each dose of YERVOY. In cases of suspected immune-mediated adverse reactions, initiate appropriate workup to exclude alternative etiologies, including infection. Institute medical management promptly, including specialty consultation as appropriate.

 

Withhold or permanently discontinue OPDIVO and YERVOY depending on severity (please see section 2 Dosage and Administration in the accompanying Full Prescribing Information). In general, if OPDIVO or YERVOY interruption or discontinuation is required, administer systemic corticosteroid therapy (1 to 2 mg/kg/day prednisone or equivalent) until improvement to Grade 1 or less. Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month. Consider administration of other systemic immunosuppressants in patients whose immune-mediated adverse reactions are not controlled with corticosteroid therapy. Toxicity management guidelines for adverse reactions that do not necessarily require systemic steroids (e.g., endocrinopathies and dermatologic reactions) are discussed below.

 

Immune-Mediated Pneumonitis

OPDIVO and YERVOY can cause immune-mediated pneumonitis. The incidence of pneumonitis is higher in patients who have received prior thoracic radiation. In patients receiving OPDIVO monotherapy, immune-mediated pneumonitis occurred in 3.1% (61/1994) of patients, including Grade 4 (<0.1%), Grade 3 (0.9%), and Grade 2 (2.1%).

 

Immune-Mediated Colitis

OPDIVO and YERVOY can cause immune-mediated colitis, which may be fatal. A common symptom included in the definition of colitis was diarrhea. Cytomegalovirus (CMV) infection/reactivation has been reported in patients with corticosteroid-refractory immune-mediated colitis. In cases of corticosteroid-refractory colitis, consider repeating infectious workup to exclude alternative etiologies. In patients receiving OPDIVO monotherapy, immune-mediated colitis occurred in 2.9% (58/1994) of patients, including Grade 3 (1.7%) and Grade 2 (1%).

 

Immune-Mediated Hepatitis and Hepatotoxicity

OPDIVO and YERVOY can cause immune-mediated hepatitis. In patients receiving OPDIVO monotherapy, immune-mediated hepatitis occurred in 1.8% (35/1994) of patients, including Grade 4 (0.2%), Grade 3 (1.3%), and Grade 2 (0.4%).

 

Immune-Mediated Endocrinopathies

OPDIVO and YERVOY can cause primary or secondary adrenal insufficiency, immune-mediated hypophysitis, immune-mediated thyroid disorders, and Type 1 diabetes mellitus, which can present with diabetic ketoacidosis. Withhold OPDIVO and YERVOY depending on severity (please see section 2 Dosage and Administration in the accompanying Full Prescribing Information). For Grade 2 or higher adrenal insufficiency, initiate symptomatic treatment, including hormone replacement as clinically indicated. Hypophysitis can present with acute symptoms associated with mass effect such as headache, photophobia, or visual field defects. Hypophysitis can cause hypopituitarism; initiate hormone replacement as clinically indicated. Thyroiditis can present with or without endocrinopathy. Hypothyroidism can follow hyperthyroidism; initiate hormone replacement or medical management as clinically indicated. Monitor patients for hyperglycemia or other signs and symptoms of diabetes; initiate treatment with insulin as clinically indicated.

 

In patients receiving OPDIVO monotherapy, adrenal insufficiency occurred in 1% (20/1994), including Grade 3 (0.4%) and Grade 2 (0.6%).

In patients receiving OPDIVO monotherapy, hypophysitis occurred in 0.6% (12/1994) of patients, including Grade 3 (0.2%) and Grade 2 (0.3%).

In patients receiving OPDIVO monotherapy, thyroiditis occurred in 0.6% (12/1994) of patients, including Grade 2 (0.2%).

In patients receiving OPDIVO monotherapy, hyperthyroidism occurred in 2.7% (54/1994) of patients, including Grade 3 (<0.1%) and Grade 2 (1.2%).

In patients receiving OPDIVO monotherapy, hypothyroidism occurred in 8% (163/1994) of patients, including Grade 3 (0.2%) and Grade 2 (4.8%).

In patients receiving OPDIVO monotherapy, diabetes occurred in 0.9% (17/1994) of patients, including Grade 3 (0.4%) and Grade 2 (0.3%), and 2 cases of diabetic ketoacidosis.

Immune-Mediated Nephritis with Renal Dysfunction

OPDIVO and YERVOY can cause immune-mediated nephritis. In patients receiving OPDIVO monotherapy, immune-mediated nephritis and renal dysfunction occurred in 1.2% (23/1994) of patients, including Grade 4 (<0.1%), Grade 3 (0.5%), and Grade 2 (0.6%).

Immune-Mediated Dermatologic Adverse Reactions

OPDIVO can cause immune-mediated rash or dermatitis. Exfoliative dermatitis, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug rash with eosinophilia and systemic symptoms (DRESS) has occurred with PD-1/PD-L1 blocking antibodies. Topical emollients and/or topical corticosteroids may be adequate to treat mild to moderate nonexfoliative rashes.

YERVOY can cause immune-mediated rash or dermatitis, including bullous and exfoliative dermatitis, SJS, TEN, and DRESS. Topical emollients and/or topical corticosteroids may be adequate to treat mild to moderate non-bullous/exfoliative rashes.

Withhold or permanently discontinue OPDIVO and YERVOY depending on severity (please see section 2 Dosage and Administration in the accompanying Full Prescribing Information).

In patients receiving OPDIVO monotherapy, immune-mediated rash occurred in 9% (171/1994) of patients, including Grade 3 (1.1%) and Grade 2 (2.2%).

Other Immune-Mediated Adverse Reactions

The following clinically significant immune-mediated adverse reactions occurred at an incidence of <1% (unless otherwise noted) in patients who received OPDIVO monotherapy or OPDIVO in combination with YERVOY or were reported with the use of other PD-1/PD-L1 blocking antibodies. Severe or fatal cases have been reported for some of these adverse reactions: cardiac/vascular: myocarditis, pericarditis, vasculitis; nervous system: meningitis, encephalitis, myelitis and demyelination, myasthenic syndrome/myasthenia gravis (including exacerbation), Guillain-Barré syndrome, nerve paresis, autoimmune neuropathy; ocular: uveitis, iritis, and other ocular inflammatory toxicities can occur; gastrointestinal: pancreatitis to include increases in serum amylase and lipase levels, gastritis, duodenitis; musculoskeletal and connective tissue: myositis/polymyositis, rhabdomyolysis, and associated sequelae including renal failure, arthritis, polymyalgia rheumatica; endocrine: hypoparathyroidism; other (hematologic/immune): hemolytic anemia, aplastic anemia, hemophagocytic lymphohistiocytosis (HLH), systemic inflammatory response syndrome, histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis), sarcoidosis, immune thrombocytopenic purpura, solid organ transplant rejection.

 

In addition to the immune-mediated adverse reactions listed above, across clinical trials of YERVOY monotherapy or in combination with OPDIVO, the following clinically significant immune-mediated adverse reactions, some with fatal outcome, occurred in <1% of patients unless otherwise specified: nervous system: autoimmune neuropathy (2%), myasthenic syndrome/myasthenia gravis, motor dysfunction; cardiovascular: angiopathy, temporal arteritis; ocular: blepharitis, episcleritis, orbital myositis, scleritis; gastrointestinal: pancreatitis (1.3%); other (hematologic/immune): conjunctivitis, cytopenias (2.5%), eosinophilia (2.1%), erythema multiforme, hypersensitivity vasculitis, neurosensory hypoacusis, psoriasis.

 

Some ocular IMAR cases can be associated with retinal detachment. Various grades of visual impairment, including blindness, can occur. If uveitis occurs in combination with other immune-mediated adverse reactions, consider a Vogt-Koyanagi-Harada–like syndrome, which has been observed in patients receiving OPDIVO and YERVOY, as this may require treatment with systemic corticosteroids to reduce the risk of permanent vision loss.

 

Infusion-Related Reactions

OPDIVO and YERVOY can cause severe infusion-related reactions. Discontinue OPDIVO and YERVOY in patients with severe (Grade 3) or life-threatening (Grade 4) infusion-related reactions. Interrupt or slow the rate of infusion in patients with mild (Grade 1) or moderate (Grade 2) infusion-related reactions. In patients receiving OPDIVO monotherapy as a 60-minute infusion, infusion-related reactions occurred in 6.4% (127/1994) of patients. In a separate trial in which patients received OPDIVO monotherapy as a 60-minute infusion or a 30-minute infusion, infusion-related reactions occurred in 2.2% (8/368) and 2.7% (10/369) of patients, respectively. Additionally, 0.5% (2/368) and 1.4% (5/369) of patients, respectively, experienced adverse reactions within 48 hours of infusion that led to dose delay, permanent discontinuation or withholding of OPDIVO.

 

Complications of Allogeneic Hematopoietic Stem Cell Transplantation

Fatal and other serious complications can occur in patients who receive allogeneic hematopoietic stem cell transplantation (HSCT) before or after being treated with OPDIVO or YERVOY. Transplant-related complications include hyperacute graft-versus-host-disease (GVHD), acute GVHD, chronic GVHD, hepatic veno-occlusive disease (VOD) after reduced intensity conditioning, and steroid-requiring febrile syndrome (without an identified infectious cause). These complications may occur despite intervening therapy between OPDIVO or YERVOY and allogeneic HSCT.

 

Follow patients closely for evidence of transplant-related complications and intervene promptly. Consider the benefit versus risks of treatment with OPDIVO and YERVOY prior to or after an allogeneic HSCT.

 

Embryo-Fetal Toxicity

Based on its mechanism of action and findings from animal studies, OPDIVO and YERVOY can cause fetal harm when administered to a pregnant woman. The effects of YERVOY are likely to be greater during the second and third trimesters of pregnancy. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with OPDIVO and YERVOY and for at least 5 months after the last dose.

 

Increased Mortality in Patients with Multiple Myeloma when OPDIVO is Added to a Thalidomide Analogue and Dexamethasone

In randomized clinical trials in patients with multiple myeloma, the addition of OPDIVO to a thalidomide analogue plus dexamethasone resulted in increased mortality. Treatment of patients with multiple myeloma with a PD-1 or PD-L1 blocking antibody in combination with a thalidomide analogue plus dexamethasone is not recommended outside of controlled clinical trials.

 

Lactation

There are no data on the presence of OPDIVO or YERVOY in human milk, the effects on the breastfed child, or the effects on milk production.

Contacts

Bristol Myers Squibb
Media Inquiries:
media@bms.com

Investors:
investor.relations@bms.com

Read full story here

Categories
Culture Local News

Mercer County offers fresh produce vouchers to qualifying, older adults

TRENTON, N.J. — Mercer County Executive Brian M. Hughes announced that starting June 1, the Mercer County Office on Aging/Aging & Disability Resource Connection (ADRC) will begin accepting applications for the Senior Farmers Market Nutrition Program, which provides vouchers for the purchase of fresh, nutritious, unprepared foods such as fruits, vegetables and herbs to low-income older adults.

 

 

“With foods provided from authorized farmers, the Senior Farmers Market Nutrition Program not only helps increase the nutritional health of our communities, but also increases the demand for locally grown produce and boosts the income of farmers who produce and sell locally grown products,” Mr. Hughes said. Last year, the Office on Aging/ADRC distributed vouchers to 1,430 Mercer County older adults, he added.

 

Eligible older adults will receive vouchers for use at participating farm stands. To qualify for this program, you must be able to verify that:

  • You are 60 years of age or older
  • You live in Mercer County
  • Your income does not exceed $23,828 per year ($1,986 monthly) if applying as a single person or $32,227 per year ($2,686 monthly) if applying as a couple*

 

Those eligible will receive five $6 vouchers for a total of $30 to spend. Vouchers will be distributed on a first-come, first-served basis. When you receive your vouchers, you also will get a listing of participating markets and vendors.

“The farmers market program offers older adults an increased opportunity to make nutritious fresh fruits and vegetables part of their daily eating choices,” Mr. Hughes said. “It also helps the older adult who may be struggling financially to get the most for their money.”

If you, a family member, or friend could benefit from this program or if you have any questions regarding it, please call the Office on Aging/ADRC at 609-989-6661 or email ADRC@mercercounty.org.

 

*Income guidelines vary for household sizes of three or more and also will change July 1 for all household sizes. Please contact the Office on Aging/Aging & Disability Resource Connection for further details.